Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy

Magali Gary-Bobo; Youssef Mir; Cedric Rouxel; David Brevet; Ouahiba Hocine; Marie Maynadier; Audrey Gallud; Afitz Da Silva; Olivier Mongin; Mireille Blanchard-Desce; Sebastien Richeter; Bernard Loock; Philippe Maillard; Alain Morere; Marcel Garcia; Laurence Raehm; Jean-Olivier Durand

doi:10.1016/j.ijpharm.2012.04.056

Retour

Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy

Article de revue

Avec comité de lecture

Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy

Magali Gary-Bobo, Youssef Mir, Cedric Rouxel, David Brevet, Ouahiba Hocine, Marie Maynadier, Audrey Gallud, Afitz Da Silva, Olivier Mongin, Mireille Blanchard-Desce, …

International journal of pharmaceutics, Vol.432(1-2), pp.99-104

01/08/2012

DOI: https://doi.org/10.1016/j.ijpharm.2012.04.056

PMID: 22569231

Résumé

Life Sciences & Biomedicine

Pharmacology & Pharmacy

Science & Technology

In this work, we focused on mesoporous silica nanoparticles (MSN) for one photon excitated photodynamic therapy (OPE-PDT) combined with drug delivery and carbohydrate targeting applied on retinoblastoma, a rare disease of childhood. We demonstrate that bitherapy (camptothecin delivery and photodynamic therapy) performed with MSN on retinoblastoma cancer cells was efficient in inducing cancer cell death. Alternatively MSN designed for two-photon excited photodynamic therapy (TPE-PDT) were also studied and irradiation at low fluence efficiently killed retinoblastoma cancer cells. (C) 2012 Elsevier B.V. All rights reserved.

Indicateurs

1 Consultations de la notice

Détails

Titre: Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy
Créateurs - sans rôle: Magali Gary-Bobo - Université Montpellier 2
Youssef Mir - Université de Rennes
Cedric Rouxel - Univ Rennes 1, CNRS UMR 6510, F-35042 Rennes, France
David Brevet - Inst Charles Gerhardt Montpellier, UMR CNRS 5253, UM2, ENSCM,UM1, F-34095 Montpellier 05, France
Ouahiba Hocine - Inst Charles Gerhardt Montpellier, UMR CNRS 5253, UM2, ENSCM,UM1, F-34095 Montpellier 05, France
Marie Maynadier - Université Montpellier 2
Audrey Gallud - Université Montpellier 2
Afitz Da Silva - Université Montpellier 2
Olivier Mongin - Université de Rennes
Mireille Blanchard-Desce - Université de Rennes
Sebastien Richeter - Inst Charles Gerhardt Montpellier, UMR CNRS 5253, UM2, ENSCM,UM1, F-34095 Montpellier 05, France
Bernard Loock - Univ Paris 11, Inst Curie, UMR CNRS 176, F-91405 Orsay, France
Philippe Maillard - Univ Paris 11, Inst Curie, UMR CNRS 176, F-91405 Orsay, France
Alain Morere - Université Montpellier 2
Marcel Garcia - Univ Montpellier 2, Univ Montpellier 1, Inst Biomol Max Mousseron UMR CNRS 5247, Fac Pharm, F-34093 Montpellier 05, France
Laurence Raehm - Inst Charles Gerhardt Montpellier, UMR CNRS 5253, UM2, ENSCM,UM1, F-34095 Montpellier 05, France
Jean-Olivier Durand - Inst Charles Gerhardt Montpellier, UMR CNRS 5253, UM2, ENSCM,UM1, F-34095 Montpellier 05, France
Détails de publication: International journal of pharmaceutics, Vol.432(1-2), pp.99-104
Éditeur: Elsevier
Nombre de pages: 6
Note de subvention: PNANO 07-102 / ANR; Agence Nationale de la Recherche (ANR) Montpellier 2 University Region Bretagne SFI20101201906 / GDR
Identifiants: 99139219309311
Unité académique: Institut Charles Gerhardt Montpellier - ICGM; Institut des Biomolécules Max Mousseron - IBMM
Langue: English
Type de ressource: Journal article